A RANDOMIZED, DOUBLE-BLIND, PLACEBO …

← Back to document page

CLINICAL PROTOCOLPHASE IIIA RANDOMIZED, double - blind , PLACEBO - controlled , MULTICENTERTRIAL OF THE SAFETY AND EFFICACY OF ceftriaxone ANDDOXYCYCLINE IN thetreatment OF PATIENTS WITHSEROPOSITIVECHRONIC LYME DISEASEInvestigators:Mark S. Klempner, , Principal InvestigatorLinden Hu, Schmid, Brown, Kaplan, C. Steere, Weinstein, R. Wormser, Danon, Dornbush, Nowakowski, Cavaliere, England Medical CenterNew York Medical CollegeClinical Studies of Chronic Lyme DiseaseNIH/NIAID Contract No. N01-AI-65308Version OF AND STUDY AND and Exclusion Evaluation Number During Dosing treatment OF INTERCURRENT of from the protocol for the Individual Patient2829New England Medical CenterNew York Medical CollegeClinical Studies of Chronic Lyme DiseaseNIH/NIAID Contract No. N01-AI-65308Version EVALUATION OF EFFICACY AND REPORT OF INFORMATION AND PUBLICATION1213XIII. COMPLETION OF STUDY14New England Medical CenterNew York Medical CollegeClinical Studies of Chronic Lyme DiseaseNIH/NIAID Contract No.

clinical protocol phase iii a randomized, double-blind, placebo-controlled, multicenter trial of the safety and efficacy of ceftriaxone and doxycycline in thetreatment of patients with

  Protocol, Controlled, Double, Doxycycline, Blind, Placebo, Ceftriaxone, Double blind, Placebo controlled, Multicenter, Ceftriaxone and doxycycline in thetreatment, Thetreatment